Circle Pharma Unveils Groundbreaking Findings on CID-078
Circle Pharma, a biopharmaceutical company in South San Francisco, is focused on developing innovative therapies using cell-permeable macrocycles that could revolutionize cancer treatment. Recently, they reached a significant milestone by presenting preclinical data on their unique cyclin A/B RxL inhibitor, CID-078, at the World Conference on Lung Cancer.
Impressive Outcomes with CID-078
CID-078 has demonstrated exceptional potential in inducing tumor regressions as a standalone treatment in preclinical models of small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). Early studies reveal that tumor models exhibiting heightened E2F targets and pronounced G2M checkpoint scores show a marked reduction in tumor growth when treated with CID-078. This effect was noted at doses that are achievable in clinical settings, laying a solid groundwork for further research.
Exploring the Mechanism of Action
The efficacy of CID-078 is closely linked to the expression levels of E2F1 and ESPL1, which aligns with its intended mechanism of inhibiting cyclin A/B RxL, ultimately resulting in DNA damage. This innovative strategy opens new pathways for targeting oncogenic processes that contribute to cancer progression.
Upcoming Clinical Trials and Research
The encouraging findings from preclinical studies indicate that CID-078 could be a promising monotherapy for patients facing these difficult cancer types. Circle Pharma is ready to move CID-078 into a phase 1 clinical trial, an important step toward making this therapy available to patients in need.
About the CID-078 Program
CID-078 has been designed as an orally bioavailable macrocycle that effectively targets tumor cells with oncogenic alterations that lead to cell cycle dysregulation. This dual-action inhibitor disrupts essential protein interactions necessary for cell cycle progression, demonstrating its potential in preclinical xenograft models where significant tumor regressions have been observed.
Circle Pharma's Dedication to Innovation
Circle Pharma is leading the way in creating distinctive macrocycle therapies, leveraging its proprietary MXMO™ platform, which combines cutting-edge synthetic chemistry with structure-based drug design. The company is committed to addressing critical unmet clinical needs, particularly focusing on cyclins that play a key role in regulating cell cycle progression and are frequently involved in various cancers.
Engaging with Circle Pharma
The company strives to provide accessible treatments that can efficiently penetrate cells through various delivery methods, including oral options. This progress not only showcases Circle Pharma's commitment to innovation but also emphasizes its aim to improve patient care through more flexible and effective medications.
Frequently Asked Questions
What is CID-078?
CID-078 is a first-and-only-in-class cyclin A/B RxL inhibitor designed to treat small-cell and non-small-cell lung cancer.
How does CID-078 work?
The inhibitor functions by disrupting protein interactions that are crucial for cell cycle progression, which leads to the inhibition and regression of tumor growth.
What stage is Circle Pharma in with CID-078?
Circle Pharma is preparing to initiate phase 1 clinical trials for CID-078, following encouraging results from preclinical studies.
What types of cancer does CID-078 target?
CID-078 specifically targets small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), both of which present significant treatment challenges.
How can I learn more about Circle Pharma?
You can find additional information about Circle Pharma's innovative therapies and research initiatives by visiting their official website.
